FDA APPROVES FIRST COAGULATION FACTOR-ALBUMIN FUSION PROTEIN
TO TREAT PATIENTS WITH
HEMOPHILIA B
The U.S. Food and Drug Administration approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.